Evaluating only Numab Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Founder chaos.
Numab raised $280M to develop multispecific antibody therapeutics for cancer, building a proprietary antibody engineering platform. Its lead cancer asset, NM21-1480, progressed into Phase 1 clinical trials. When early Phase 1 data showed insufficient evidence of efficacy and dose-limiting toxicities appeared at therapeutic doses, Numab was unable to justify continued clinical investment. The company wound down all operations in 2023, returning remaining capital to shareholders.
Lesson
“Platform biotech companies raise capital on the promise that a proprietary platform creates multiple therapeutic opportunities. When the first clinical asset fails, the platform narrative collapses: investors funded the pipeline, not the science.”